Palliative Care for Alzheimer's in the New Era of Amyloid Antibody Treatments

A new era is emerging in the treatment of Alzheimer’s disease due to the development of monoclonal antibodies that target β-amyloid in the brain. These drugs are not without controversy as they do not stop or reverse the progression of the disease. Rather, at best, they slow down the progression of Alzheimer’s and come with a significant cost and risk to the patients who take them.

This CAPC Interprofessional Grand Rounds discussion will delve into the increasingly crucial role of palliative care in the management of Alzheimer's disease amidst the arrival of these new amyloid antibody treatments. The presenters, a physician, chaplain, and nurse practitioner, will explore how palliative care can enhance quality of life by addressing the multifaceted needs of patients and caregivers throughout the disease trajectory. The session will also provide insights into the latest advancements in amyloid antibody therapies, highlighting their potential benefits and associated risks.

As the treatment landscape for Alzheimer's evolves, the importance of aligning care with patient values and preferences becomes paramount. This presentation will underscore the significance of palliative care in facilitating discussions around goals of care, medication management, and timely hospice referral, ensuring a holistic approach to care that respects the dignity and wishes of those affected by Alzheimer's.